CTOs on the Move

Keryx

www.keryx.com

 
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a team of approximately 200 committed people working with passion to identify meaningful new medicines to advance the care of people with kidney disease. We have assembled a deep concentration of kidney care experts, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. Together, we strive to raise awareness of the kidney disease epidemic, give voice to this underserved population, and help healthcare professionals to improve the care of their patients. In September 2014, the U.S. Food and Drug Administration approved Keryx`s first medicine, Auryxia® (ferric citrate) tablets. Keryx established its corporate headquarters in ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.keryx.com
  • One Marina Park Drive Twelfth Floor
    Boston, MA USA 02210
  • Phone: 212.531.5965

Executives

Name Title Contact Details
Michael Crispin
 Vice President of Technology and Digital Operations Profile

Similar Companies

Allucent

Allucent is a global biopharmaceutical services company founded in 2022 through the merger of several specialized providers. The company focuses on supporting small and mid-sized biotech firms in developing innovative treatments for patients with unmet medical needs. With over 30 years of combined experience, Allucent offers a range of services including regulatory consulting, clinical operations management, biometrics, and clinical pharmacology, particularly emphasizing oncology. Headquartered in Cary, North Carolina, Allucent has a strong global presence with offices in North America, Europe, Central/Eastern Europe, and Asia/Middle East. The company has conducted more than 825 clinical trials across over 70 countries, showcasing its extensive operational expertise. Allucent is dedicated to helping clients navigate the complexities of drug development and regulatory approval, ultimately accelerating the delivery of breakthrough therapies to patients.

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.

Centocor

Aurora Biomed

Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunomedics

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.